Carcinogenicity Studies for Anti-Aging Drug Development

The demand for safe anti-aging therapeutics requires a rigorous evaluation of their potential to induce carcinogenicity. Carcinogenicity studies are designed to assess whether a drug can cause cancer by promoting the uncontrolled growth of cells. They are a regulatory requirement for marketing approval, and the data obtained from these studies are essential for demonstrating drug safety.

Fig. 1 The three stages of carcinogenesis; initiation, promotion, and progression. (Pérez-Carreón JI and Meléndez-Zajgla J, 2012)

At CD BioSciences, we are committed to helping clients assess the safety and efficacy of anti-aging drugs through comprehensive carcinogenicity studies. We focus on understanding the mechanisms by which anti-aging drugs may affect cellular processes that may lead to tumorigenesis.

How Do We Analyze the Carcinogenicity of Anti-Aging Drugs?

CD BioSciences helps clients integrate in vitro and in vivo assays to assess each anti-aging drug's carcinogenic potential.

In vitro carcinogenicity studies

We offer assays such as the Ames test, micronucleus test, and comet assay to evaluate anti-aging drug mutagenic potential and provide early insights into their carcinogenic risks. We help clients perform MTT and BrdU assays to determine how anti-aging drugs affect cell proliferation and viability. We also conduct assays to evaluate how anti-aging drugs affect programmed cell death (apoptosis) and cell cycle progression, which is critical for unveiling the potential of anti-aging drugs to induce cancer.

In vivo carcinogenicity studies

We help clients conduct extensive long-term studies in rodent models to evaluate the potential carcinogenic effects of anti-aging drugs. We also monitor tumor development in treated and control groups. Additionally, we assist in establishing how different drug doses affect tumor development, allowing for risk assessment.

What Experimental Models Do We Offer for Carcinogenicity Studies?

At CD BioSciences, we utilize experimental models to provide relevant data for carcinogenicity studies in anti-aging drug development.

Human cell lines

For preliminary screening, we offer a variety of established human cell lines from different tissues and cancer types. Our services allow a quick assessment of the carcinogenic potential of anti-aging drugs before moving on to more complex models.

Rodent models

Rodent models are the standard for carcinogenicity testing due to their well-understood biology and relevance to humans. We employ various mouse, rat, and hamster strains that may reflect human-like responses to anti-aging drugs. We have expertise in different routes of administration, including oral, inhalation, dermal, and subcutaneous routes.

Transgenic models

For carcinogenicity studies, we use transgenic animals carrying specific oncogenes or tumor suppressor genes, such as rasH2, p53 +/-, and Tg. AC mouse models. We use these models to help clients study the mechanisms of carcinogenesis induced by anti-aging drugs to assess genetic susceptibility.

At CD BioSciences, our carcinogenicity studies for anti-aging drug development provide a robust and thorough evaluation of the potential carcinogenic risks posed by new drug candidates. Our expertise ensures that our clients receive high-quality data to support their drug development projects. If you are interested in our services, please feel free to contact us or make an online inquiry.

Reference

1. Pérez-Carreón JI, Meléndez-Zajgla J. In vitro and in vivo models for cancer research. Molecular Oncology Principles and Recent Advances, 2012, 148-162.